TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06727136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBP-PI-HBr
Description: TBP-PI-HBr film-coated immediate-release tablets
Study: NCT05094297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Investigate the effects of an exercise intervention on U.S. Veterans.
Description: Enrolled subjects will be asked to complete 94 total visits (4 study testing visits and 90 exercise visits). They will be tested for fitness, strength, and health risk factors at UIC 4 times and will complete 90 exercise training visits at the GH FITLab over the next 18 months.
Study: NCT06593574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic laminectomy
Description: Surgical robots are used to assist with laminectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional laminectomy
Description: Instead of relying on a surgical robot, doctors perform the laminectomy themselves with an ultrasonic osteotome
Study: NCT06651580

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, saliva, urine or stool samples
Study: NCT05215951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Dose Formulation: tablet； Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration
Study: NCT06651580

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete QoL assessment

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT06651463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videorecording
Description: Two cameras will be used to make the recordings: a classic camera placed on a stand 1 meter from your head, outside the sterile area and the color camera of the microscope used for the surgery.
Study: NCT05089591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intense Pulsed Light therapy
Description: The LacryStim System is a CE marked device for treatment of meibomian gland dysfunction. It stimulates and reactivates meibomian glands and improves the related dry eye condition. Intense pulsed light is emitted with a light spectrum from 610nm to 1200nm. Each treatment consists of short individual pulses lasting for 4ms separated by a 26ms lasting interval to hinder tissue temperature increase, thermal damage to the skin and inflammatory reaction. During this phase 8 to 12 J / cm2 are delivered. Selection of total energy levels depends on the skin type (Fitzpatrick Skin Types) as recommended by the manufacturer.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: The fellow eye serves as the control eye. Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations). The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.
Study: NCT06727136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBP-PI-HBr
Description: TBP-PI-HBr film-coated immediate-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBP-PI-HBr
Description: TBP-PI-HBr film-coated immediate-release tablets
Study: NCT06725784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReHandyBot
Description: The ReHandyBot is a platform for hand rehabilitation with two degrees of freedom, namely forearm pronation/supination and finger flexion/extension. This device allows performing exercises targeting somatosensation and motor functions. Different exercises are implemented using virtual reality and haptic feedback; the interaction forces between subjects and ReHandyBot are measured by force sensors in the handles, allowing the control of a virtual hand and the physical interaction with the virtual environment. Mechanical properties (e.g., size, stiffness) of the objects displayed in the virtual environment are rendered by the motion/force of the instrumented handles. The type and difficulty level of the exercises are patient-specific and are automatically adapted throughout the therapy.~The duration and frequency of the therapy sessions with ReHandyBot depend on the specific patient's needs and are set according to the therapist's instructions.
Study: NCT06727071

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hyperglycemic clamp
Description: A continuous infusion of 20% dextrose will be maintained throughout the procedure, while a variable rate of insulin infusion will be used to control participants blood glucose level.
Study: NCT06725498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab-jsgr
Description: 200mg, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60-75 mg/㎡, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 260 mg/㎡, Q3W

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radical Radiotherapy or adjuvant Radiotherapy per guidelines.
Study: NCT06726642

Intervention type: DIAGNOSTIC_TEST
Intervention: Cell-free DNA analysis
Description: Analysis of cell-free DNA in blood plasma will involve targeted sequencing of key cancer-related genes, cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq), and shallow whole genome sequencing (sWGS).
Study: NCT06726265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eftilagimod alfa
Description: 30 mg of efti every 2 weeks subcutaneously for the first 6 months, thereafter every 3 weeks for up to 24 months in total

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin plus paclitaxel
Description: For patients with squamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: carboplatin area under the curve (AUC) 5 or 6 in combination with paclitaxel 175 mg/m2 or 200 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin plus paclitaxel
Description: For patients with squamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: carboplatin area under the curve (AUC) 5 or 6 in combination with paclitaxel 175 mg/m2 or 200 mg/m2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin or carboplatin + pemetrexed
Description: For patients with nonsquamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: cisplatin 75 mg/m2 or carboplatin AUC 5 or 6 in combination with pemetrexed 500 mg/m2. After the initial 4 cycles, pemetrexed 500 mg/m2 maintenance therapy will be administered every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin or carboplatin + pemetrexed
Description: For patients with nonsquamous histology for 4 cycles (1 cycle = 3 weeks) as follows: every 3 weeks: cisplatin 75 mg/m2 or carboplatin AUC 5 or 6 in combination with pemetrexed 500 mg/m2. After the initial 4 cycles, pemetrexed 500 mg/m2 maintenance therapy will be administered every 3 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab (KEYTRUDA®)
Description: 200 mg pembrolizumab (KEYTRUDA®) every 3 weeks i.v. for up to approximately 24 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: 200 mg pembrolizumab (KEYTRUDA®) every 3 weeks i.v. for up to approximately 24 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: efti-matching placebo every 2 weeks subcutaneously for the first 6 months, thereafter every 3 weeks for up to 24 months in total
Study: NCT06725927

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Description: Influenza vaccination pre-discharge in patients hospitalized due to heart failure exacerbation
Study: NCT06726629

Intervention type: OTHER
Intervention: Version Of The New Knee Society Knee Scoring System
Description: All patients will be subjected to the same clinical and radiographic checks, the data of which will be collected in the different centres
Study: NCT05030168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketosteril
Description: ketoanalogues of essential amino acid
Study: NCT06653699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 DOSES OF DEXAMETHASONE AND TRANEXAMIC ACID
Description: In group B, 2 doses of 10 mg intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
Study: NCT06507930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Hospice Visits
Description: Telehealth check-in appointments with oncology care team, MD, PA, NP, or hospice nurse, via HIPAA compliant telehealth platform, Zoom, or by phone call.
Study: NCT05899374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KindMap
Description: The KindMap is a stand-alone, cost-free e-mental health tool presenting a low-intensive psychological intervention adapted from the MBPI to fit a web app format. KindMap is to be used at users' own time and pace, and includes ten modules addressing psychoeducation, mindfulness and compassion guided practices, and ACT-based experiential exercises. These components are delivered through text, videos, audio, experiential exercises, and interactive contents.
Study: NCT05350449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loving-kindness Meditation
Description: Loving-kindness meditation is a type of mindfulness practice where the focus is on love/compassion and kindness for self and others. The guided meditation will be provided via recording device. The intervention is 4 week long.
Study: NCT05286502

Intervention type: DEVICE
Intervention: fundus photography
Description: color fundus photography
Study: NCT05154253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomotum Spark: Robotic ankle assistance
Description: A lightweight assistive wearable ankle robotic device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomotum Spark: Robotic ankle resistance
Description: A lightweight resistive wearable ankle robotic device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard gait training
Description: Standard gait training without a device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Description: Standard ankle foot orthosis
Study: NCT06653699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 DOSE OF DEXAMETHASONE AND TRANEXAMIC ACID
Description: In group A, 1 dose of 10 mg of intravenous dexamethasone and 20mg/kg of intravenous tranexamic acid administered.
Study: NCT05154253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physical therapy
Description: Physical therapy without a device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard walking
Description: Walking without a device
Study: NCT05524584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given orally
Study: NCT05858372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chios Mastiha essential oil
Description: 1 soft gel capsule containing 200 mg of CMO and 100 mg of other excipients being medium chain triglycerides, while the shell was made of bovine gelatin and glycerol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05798221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complementary self-help strategies in addition to treatment as usual
Description: The 10-week group program consists of self-help strategies from complementary medicine approaches of TEM (Traditional European Medicine), TCM (Traditional Chinese Medicine), and TIM (Traditional Indian Medicine) in addition to treatment as usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The active control group consists a 16-week waiting period, where treatment as usual is allowed. In case of acute worsening/progression of the symptoms, consultations with the study physician are offered anytime. After the waiting period, the control group will be offered the same units as in the experimental group.
Study: NCT05935332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPT193
Description: RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05590052

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Electrosurgery
Description: Achievement of hemostasis using bipolar electrosurgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermocautery
Description: achievement of hemostasis using thermocautery
Study: NCT05941234

Intervention type: OTHER
Group type: OTHER
Intervention: Biological biomarker analysis
Description: Collection of tumor and blood samples at T0 (surgery) and T1 (6 months follow-up) Tumor microenvironment and blood multi-omics analysis In-depth functional characterization of tumor microenvironment Cancer stem cells generation and drug testing Data integration by business intelligence and development of AI-based prognostic markers
Study: NCT06550219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal humidified heated high flow cannula (NHHHC)
Description: Patients in this arm will receive humidified heated high flow using Vapotherm device, USA. Stating with 2 L/min flow and increase gradually till 8L/minute, guided by oxygen requirements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Description: Patients in this arm will receive both PEEP (positive end expiratory pressure ) and PIP (peak inspiratory pressure) using SLE 5000/6000 device, UK . Pressures will be adjusted according to severity of respiratory distress.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure NCPAP
Description: Patients in this arm will receive PEEP (positive end expiratory pressure ), stating from 5 mbar to reach maximally 8 mbar.
Study: NCT05806658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual arts-based intervention
Description: This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
Study: NCT06550219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: Lung ultrasound (LUS) machine is a mobile device (Philips HDll XE, USA) with s8-3 probe with a frequency range of 8-3 MHz will be used as ultrasound machine. Throughout the period of non-invasive respiratory support Patient will be monitored by: LUS,Heart rate, Respiratory rate, Mean arterial pressure, Oxygen saturation index, Oxygen index, PaO2, blood gases and Fractional inspired oxygen (Fio2).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: Lung ultrasound (LUS) machine is a mobile device (Philips HDll XE, USA) with s8-3 probe with a frequency range of 8-3 MHz will be used as ultrasound machine. Throughout the period of non-invasive respiratory support Patient will be monitored by: LUS,Heart rate, Respiratory rate, Mean arterial pressure, Oxygen saturation index, Oxygen index, PaO2, blood gases and Fractional inspired oxygen (Fio2).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: Lung ultrasound (LUS) machine is a mobile device (Philips HDll XE, USA) with s8-3 probe with a frequency range of 8-3 MHz will be used as ultrasound machine. Throughout the period of non-invasive respiratory support Patient will be monitored by: LUS,Heart rate, Respiratory rate, Mean arterial pressure, Oxygen saturation index, Oxygen index, PaO2, blood gases and Fractional inspired oxygen (Fio2).
Study: NCT05163483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab
Description: Tucidinostat (chidamide), 30mg, po., biw, q3w Toripalimab, 240mg, ivgtt., d1, q3w Bevacizumab, 7.5mg/kg, ivgtt., d1, q3w~approximately 2 years
Study: NCT05609513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HTN-BASIC
Description: The HTN-BASIC intervention will consist of providing consistent access to diagnostic equipment and evidence-based antihypertensive drugs at no cost to the hypertensive patients. Access to a consistent supply of three anti-hypertensive drugs (amlodipine 5, 10mg; valsartan 80, 160mg; and hydrochlorothiazide 12.5, 25mg) will be supplied to each clinic in the trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HTN-PLUS
Description: In addition to receiving all the components of HTN-BASIC, HTN-PLUS sites will receive an enhanced, more human-resource intensive package of interventions that have been developed in consultation with key stakeholders during our human-centered design phase. The intervention components will include four broad categories- (1) hypertension training, (2) differentiated service delivery and (3) remote patient monitoring for hypertension and (4) Performance Improvement Program. Uptake of all components will be assessed on a monthly basis during the intervention period. These interventions will by nature cost more, and so cost data will be rigorously collected as well.
Study: NCT06298721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized outcome prediction tool + targeted interventions
Description: * TKA Personalized Outcome Prediction Tool to aid in setting expectations~* Mental Health Screening/Intervention~* Physical Therapy Pre-surgery Assessments \& Rehabilitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care TKA
Description: - Standard of care preoperative TKA clinic appointment to discuss plan for surgery and get consent
Study: NCT04951752

Intervention type: DRUG
Intervention: Ropivacaine injection
Description: Transmuscular quadratus lumborum block - active

Intervention type: DRUG
Intervention: Ropivacaine injection
Description: Transmuscular quadratus lumborum block - active

Intervention type: DRUG
Intervention: Ropivacaine injection
Description: Transmuscular quadratus lumborum block - active

Intervention type: DRUG
Intervention: Ropivacaine injection
Description: Transmuscular quadratus lumborum block - active

Intervention type: DRUG
Intervention: Ropivacaine injection
Description: Transmuscular quadratus lumborum block - active
Study: NCT05317065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfullness Based Stress Reduction (MBSR) intervention
Description: Mindfullness Based Stress Reduction (MBSR) intervention: Monitoring stress and anxiety levels with mindfulness program
Study: NCT06525779

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of macintosh laryngoscope
Description: The requirement of external laryngeal manipulation recorded in use of macintosh vs mcGrath laryngoscope in double lumen tube insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of mcGarth laryngoscope
Description: Use of mcGarth laryngoscope
Study: NCT06187103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HyperSight Imaging
Description: Patients receive standard of care radiation treatment on a Varian TrueBeam system equipped with HyperSight CBCT imaging. Images acquired for daily patient positioning from two different treatment fractions - typically one near the beginning of the treatment course and one at about the halfway point - will be analyzed for the study.
Study: NCT06328790

Intervention type: OTHER
Intervention: Multidisciplinary Rehabilitation Training
Description: 34 Patients will attend the in-person 5-day rehabilitation program (2 h/day) followed by a 12-weeks telemedicine program (1 h/week).

Intervention type: BEHAVIORAL
Intervention: Cross-sectional study on patients with FMD and patients with structural/organic diseases
Description: Each subject will undergo behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and interoceptive domains.

Intervention type: BEHAVIORAL
Intervention: Cross-sectional study on patients with FMD and healthy controls (HC)
Description: Each subject will undergo a set of behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and
Study: NCT06167304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-implemented exercise therapy
Description: Therapy plans are performed at home overseen by a remote physical therapist via SimpleTherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Traditional physical therapy per Standard of care.
Study: NCT06109064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Unrelated Umbilical Cord Blood
Description: The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.
Study: NCT06328790

Intervention type: BEHAVIORAL
Intervention: Cross-sectional study on patients with FMD and healthy controls (HC)
Description: Each subject will undergo a set of behavioural, neurophysiological, and Magnetic Resonance Imaging (MRI) tests exploring the motor, exteroceptive and
Study: NCT05630352

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
Description: Injection in the muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 1 microgram dose
Description: Injection in the muscle
Study: NCT06381349

Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Alimetry test
Description: Gastric Alimetry test will be performed within 30-days prior to G-POEM procedure. It's results will not inform clinical management in this observational study.
Study: NCT04959526

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Shear-wave elastography
Description: Ultrasound based imaging of diaphragm muscle activity
Study: NCT06109064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)
Study: NCT05082493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berubicin Hydrochloride
Description: Berubicin will be administered as 1-hour infusions each day for 3 consecutive days followed by 18 days off drug (ie, 21-day cycles). The starting dose is based on population PK modeling of data from adult studies and will be 1.20 mg/m2 (Dose Level 1). During the study, PK data will be incorporated into a PK model on an ongoing basis and may be used to inform dose escalation decisions